Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Pharmacol. 2012 Dec;12(6):704-9. doi: 10.1016/j.coph.2012.06.013. Epub 2012 Jul 18.

Is there a future for prenyltransferase inhibitors in cancer therapy?

Author information

1
Department of Internal Medicine, University of Iowa, C32 GH, Iowa City, IA 52242, USA.

Abstract

It has been over 20 years since it was first recognized that the function of both normal and oncogenic Ras is dependent on the post-translational modification termed farnesylation. Since that time, intense effort has been expended on the development of farnesyltransferase inhibitors as novel anticancer agents. Over 70 clinical trials have now been conducted, with limited efficacy demonstrated. Here we provide an update of the most recently published clinical trials, discuss the use of the RASGRP1/APTX two-gene expression screen to select patients with acute myeloid leukemia for therapy, and report on the latest discoveries related to the targets of prenyltransferase inhibitors.

PMID:
22817869
DOI:
10.1016/j.coph.2012.06.013
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center